

Annex A

EU (MA) number	Invented name	Strength	Pharmaceutical form	Target species	Route of administration	Immediate packaging	Content	Package size	Withdrawal period
EU/2/19/244/001	Nobivac Myxo-RHD PLUS	--1	Lyophilisate and solvent for suspension for injection	Rabbits	Subcutaneous use	Lyophilisate: vial (glass) and solvent: vial (glass)	Lyophilisate: 1 dose, solvent: 0.5 ml	In plastic box: Lyophilisate: 5 vials, solvent: 5 vials	Zero days
EU/2/19/244/002	Nobivac Myxo-RHD PLUS	--1	Lyophilisate and solvent for suspension for injection	Rabbits	Subcutaneous use	Lyophilisate: vial (glass) and solvent: vial (glass)	Lyophilisate: 1 dose, solvent: 0.5 ml	In plastic box: Lyophilisate: 25 vials, solvent: 25 vials	Zero days
EU/2/19/244/003	Nobivac Myxo-RHD PLUS	--1	Lyophilisate and solvent for suspension for injection	Rabbits	Subcutaneous use	Lyophilisate: vial (glass) and solvent: vial (glass)	Lyophilisate: 50 doses, solvent: 10 ml	In cardboard box: Lyophilisate: 10 vials, In cardboard box: Solvent: 10 vials	Zero days

--1 Live myxoma vectored rabbit haemorrhagic disease (RHD) virus:

Strain 009: $\geq 10^{3.0}$ and $\leq 10^{5.8}$ FFU*

Strain MK1899: $\geq 10^{3.0}$ and $\leq 10^{5.8}$ FFU*

*Focus Forming Units